Alaska Medical Assistance DUR Committee Meeting Minutes

Friday, April 15th, 2022

Meeting was held telephonically due to COVID-19. 1:00 PM

Drug Utilization Review Committee Attendees

Members Present	Non-Members Present
Erin Narus, PharmD (DHSS)	Umang Patel, PharmD (Magellan)
Charles Semling, PharmD (DHSS)	Ryan Ruggles, PharmD, MSHI (Magellan)
Charles Ryan, MD	
Barb Piromalli, DO	
Jonathon Harrison, PharmD	
Keri McCutcheon, RPh	Members Absent
Matthew Begay-Bruno, PharmD	
Robert Carlson, MD	

Call to order at 1:04 PM.

Charles Semling asked for all members of the public to identify themselves.

Review of minutes from March 2022

Charles Semling will be sending out the minutes shortly for the committees review.

Review of Agenda

Charles Semling went over the agenda for the committee members.

Overview of Medicaid Prescription and Cost Trends

Drug utilization was presented to the committee and it was shown that there was an increase in the last month. It was noted that there more members and utilizers in the last month especially when compared to the same month last year.

Top 10 categories were shown, and it was mentioned that antivirals and antidiabetics were driving some of the cost.

Top 25 reports were shown to the committee. It was mentioned that the hemophilia drugs do not take many claims to put them in the top list. The Vivitrol change and Dupixent were pointed out in the top 25 rankings in

net-net expenditures. The top 25 graphs for amount changed were shared with the committee. Ozempic, Humira and Mavyret stood out as previous month to current month changes.

Prospective Drug Utilization Review/Clinical Topic Areas

New Prescription Medications (Interim PA List – 6 month review)

New items proposed for the interim PA list was presented to the committee.
Keri McCutcheon moved to approve the addition of the drug list.
seconded.
No committee opposition.

Bonjesta could be added to Diclegis criteria due to being similar to Diclegis which has criteria and Charles Semling requested that the committee approve the criteria for that drug.
Charles Ryan moved to approve the addition.
Keri McCutcheon seconded.

Quviviq could be added to Belsomra criteria due to being similar to Belsomra which has criteria and Charles Semling requested that the committee approve the criteria for that drug.
Charles Ryan moved to approve the addition.
No committee opposition.

The state recommended that Tobi inhalation solution have it's criteria removed due to low claim count and having had outlived it's useful life.
Robert Carlson moved to approve.
No committee opposition.

New Prior Authorizations, Quantity Limits, Edits

Soliris and Ultomiris criteria was presented. The committee noted that the criteria was to the label, and that there was not a lot of debate to be had.
Keri McCutcheon moved to approve.
Robert Carlson seconded.
No committee opposition.

Duchenne Muscular Dystrophy criteria was presented.
Charles Ryan moved to approve.
Keri McCutcheon seconded.
No committee opposition.

Charles Semling made a comment regarding the formulary and the difference between the Preferred Drug List which is a subset of the entire formulary and that it is not all encompassing. He commented on the definition of covered outpatient drug and the reason behind having criteria is to ensure that products are used appropriately.

Krystexxa criteria was presented.
Keri McCutcheon moved to approve.
Matthew Begay-Bruno seconded.

No committee opposition.

Zulresso criteria was presented. The committee clarified that the drug was used once, and Charles Semling clarified that it was once per pregnancy. The committee also inquired if the patient would have to meet the criteria for each subsequent pregnancy. The State clarified that the trials from previous pregnancies would count toward subsequent approval.
Keri McCutcheon moved to approve.
Matthew Begay-Bruno seconded.
No committee opposition.

Evrysdi and Spinraza criteria was presented. The committee had questions regarding the requests from the letters from practitioners regarding the criteria. The committee was in favor of removing criteria point number four. Washington criteria was reviewed as a comparative tool to the proposed criteria. The committee commented that they preferred the language of requiring baseline and annual documentation of various tests or exams. There was conversation regarding the age of approvals and the differences between age of diagnosis. The idea of collecting outcomes data through this process was discussed. The committee decided to relook at this criteria in the September meeting and Charles Semling will be looking at other State's criteria to see how it compares.
No committee opposition.

Jynarque and Samsca criteria was presented. Samsca is the same drug, and only the Samsca criteria was added.
Keri McCutcheon moved to approve.
Charles Ryan seconded.
No committee opposition.

Opioid tables were reviewed with the committee. Many reductions over time were noted. The new proposed CDC guidelines were mentioned. It was noted that there was not very much pushback from providers or from patients regarding the current opioid policies. There was some discussion about the CDC new guidelines. ICD10 compliance was shown to the committee, and the pharmacies that had improved since the January letter was sent was noted.

FDA Label Changes/FAERS Reports

FDA investigating possible increased risk of death with Ukoniq and are suspending enrolling new patients in their trial.

Oral buprenorphine has increased risk dental problems such as tooth decay, cavities, and loss of teeth.

FAERS reports were shown to the committee.

End of Public Meeting

Adjournment 3:23 p.m.

Next meeting date September 16th, 2022.